Related Experiment Video

Updated: May 31, 2026

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Novel therapies for Pseudomonas aeruginosa pneumonia

Damien Roux1, Jean-Damien Ricard

  • 1INSERM U722, UFR de Médecine, Université Denis Diderot-Paris 7, Paris, France.

Infectious Disorders Drug Targets
|June 18, 2011
PubMed

Insights

Pseudomonas aeruginosa causes severe pneumonia, leading to antibiotic resistance. New strategies like immunotherapy and targeting Candida may offer future treatment options.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pulmonology

Background:

  • * Pseudomonas aeruginosa is a primary cause of hospital-acquired and ventilator-associated pneumonia.
  • * Its virulence is linked to genomic factors, quorum sensing (QS), and the type III secretion system.
  • * Antibiotic resistance in P. aeruginosa severely limits treatment options.

Purpose of the Study:

  • * To review current and emerging therapeutic strategies for P. aeruginosa pneumonia.
  • * To highlight the challenges posed by antibiotic resistance.
  • * To explore novel approaches including immunotherapy, QS inhibition, and adjunctive therapies.

Main Methods:

  • * Review of existing literature on P. aeruginosa pathogenesis and treatment.
  • * Analysis of novel therapeutic strategies: immunotherapy (anti-PcrV, phagocytosis enhancement), QS inhibition, antibacterial peptides.
  • * Evaluation of antibiotic revival (colistin) and alternative delivery methods (aerosol).
  • * Consideration of co-infections, specifically Candida colonization.

Main Results:

  • * Immunotherapy targeting the type III secretion system and enhancing phagocytosis shows promise.
  • * Quorum sensing inhibition is effective in vitro and in vivo.
  • * Colistin demonstrates clinical efficacy despite resistance concerns.
  • * Topical aerosol delivery may improve antibiotic concentration and reduce toxicity.
  • * Candida airway colonization is associated with P. aeruginosa pneumonia, suggesting a role for its reduction.

Conclusions:

  • * P. aeruginosa pneumonia presents significant treatment challenges due to virulence and resistance.
  • * Emerging therapies like immunotherapy and QS inhibition offer new avenues.
  • * Addressing Candida co-colonization may be crucial for comprehensive patient care.
  • * Combination strategies are essential for combating this resilient pathogen.

More Related Videos

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Gene Regulation in Microbial Communities: Quorum Sensing01:28

Gene Regulation in Microbial Communities: Quorum Sensing

Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...